Romano Brothers AND Company Sells 425 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Romano Brothers AND Company decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,222 shares of the biopharmaceutical company’s stock after selling 425 shares during the quarter. Romano Brothers AND Company’s holdings in Gilead Sciences were worth $1,335,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Tompkins Financial Corp lifted its stake in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. Sachetta LLC bought a new position in Gilead Sciences during the fourth quarter worth about $30,000. Finally, Rakuten Securities Inc. bought a new position in Gilead Sciences during the fourth quarter worth about $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Barclays decreased their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, Wells Fargo & Company lowered their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. Twelve research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Stock Down 0.3 %

Shares of NASDAQ GILD opened at $68.61 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The stock’s fifty day moving average is $65.98 and its 200 day moving average is $72.58. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The stock has a market capitalization of $85.48 billion, a P/E ratio of 190.58, a PEG ratio of 2.92 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the company earned $1.37 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.